Updates About the Expanded Access Program for MN-166 in ALS
Program to provide investigational drug to ALS patients who would otherwise be ineligible for clinical trials SAN JOSE, Calif., June 29, 2026 /PRNewswire/ -- WideTrial is pleased to share that the Expanded Access Program it launched in 2025, Scalable Expanded Access with Analysis of...
Program to provide investigational drug to ALS patients who would otherwise be ineligible for clinical trials SAN JOSE, Calif., June 29, 2026 /PRNewswire/ -- WideTrial is pleased to share that the Expanded Access Program it launched in 2025, Scalable Expanded Access with Analysis of...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.